Pharmaceutical manufacturer for Oxaliplatin

Fresenius Kabi operates as an international healthcare organization specializing in essential medications and advanced technologies for intravenous therapy, blood transfusion, and medical nourishment. The company's portfolio is instrumental in supporting the needs of severely and persistently unwell individuals. Additionally, it provides a variety of active pharmaceutical ingredients (APIs) and finalized goods fabricated within its own establishments

Established in 1958, Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs). Qilu currently has 12 subsidiaries, 11 domestic manufacturing sites and over 3,9000 employees worldwide. Qilu ranks among Top 5 in Chinese pharmaceutical industry in 2022. Dedicated to offering high-quality & trustworthy medicines to the world and improving people‘s well-being, Qilu is vigorously exporting its products to over 100 countries and regions around the world.

Fresenius is an international healthcare conglomerate offering products and services for kidney dialysis, hospital care, and home medical treatment. The Fresenius Group comprises four distinct business segments - Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed - each managing its own global operations.

Sicor, situated in the northern region of Italy, is a component of the Teva API business and offers a worldwide platform for the production and promotion of APIs for injectable, inhalation, topical, and nasal products. These specialized facilities possess a significant level of skill, manufacturing approximately 60 active pharmaceutical ingredients.

In just over a decade, Laurus has positioned itself as one of the largest and most innovative API producers globally. Expanding upon its established expertise in chemistry, Laurus has recently adopted full vertical integration, including a strong finished dosage capacity, dedicated capacity for backward integration, and also Synthesis R&D operations in India and the USA.

We specialize in premium Active Pharmaceutical Ingredients (APIs), Formulations, Innovative Drug Delivery Systems, and Specialty Chemicals using advanced technology with precision to adhere to global standards/specifications. Presently, we are recognized as one of the foremost global providers of Oncology/non-Oncology APIs, intermediates, and Formulations. Shilpa Medicare’s establishments have garnered significant regulatory endorsements from USFDA, EUGMP, TGA, PMDA, Cofepris, Anvisa, and KFDA, encompassing diverse regulatory approved manufacturing standards.

Emcure Pharmaceuticals is driven by the purpose to develop, manufacture and market a broad range of pharmaceutical products globally. Our core strength and competitive advantage lie in our established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others. Emcure has launched 6 Biologics in the Domestic Market & RoW markets & they are the domestic leader in three biologics. With 350+ brands, five R&D centers and 13 manufacturing facilities established across the country, we have ensured a strong presence not just in India but also outside India with a wide network across 70+ countries. Our API facilities ensures that our supply chain is vertically integrated providing flexibility over control of manufacturing. We have cemented strategic global partnerships that are a result of alliances with local and multi-national companies which are at the helm of leadership in key therapeutic areas. The key objective of our widespread presence across markets is to constantly innovate and deliver affordable & high-quality healthcare solutions to people.

Veranova boasts over 50 years of expertise and is a frontrunner in the creation and fabrication of intricate and specialized APIs for the pharmaceutical and biotech sectors. It was previously a segment of Johnson Matthey, specializing in intricate and regulated chemical processes. The company delivers customized services throughout all phases of drug development and is split into Generics and Originators. It possesses a variety of development technologies and areas of expertise, along with a cooperative approach to API manufacturing and procedures.

Founded in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise featuring whole chain, multi-regional integration of research, production and marketing as well as development of drug substances and preparations. In 2000, an A-share was issued in order to enter the stock market as a state-owned listed company. As of 2021, Hisun Pharmaceutical is now one of the largest producers of antibiotics and anti-tumor drugs in China and has been listed in the Top 500 Chinese manufacturing enterprises and the Top 100 Chinese pharmaceutical enterprises multiple times. In 2020 Hisun Pharmaceuticals received special recognition from the Joint Prevention and Control Team from the State Council of the People’s Republic of China for their extraordinary efforts in the fight against the epidemic, and Hisun Pharmaceutical was awarded with the “Anti COVID-19 Advanced Collective in Ministry of Industry and Information Technology".

Mac-Chem has a National and Global footprint with a wide presence across the globe. Mac-Chem has carved a niche for itself in the exceedingly competitive and quality conscious sphere of Active Pharmaceutical Ingredients (API) manufacturing with US-FDA, EDQM, COFEPRIS, ANVISA, MFDS-Korea, WHO-GMP and ISO certified facilities

We are committed to providing innovative and quality medicines to the nearly 200 million people we serve around the world every day; we make contact with patients, families and communities for better health and better days.

Haorui, established in the year 1997, operates as a manufacturer and provider of APIs, pharmaceutical intermediates, veterinary products, and food additives. Furthermore, it aids international pharmaceutical firms in achieving domestic registration for their finished dosage forms to support their global expansion efforts. The company's array of USFDA approved products includes Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, and Dasatinib Monohydrate among others. Its headquarters is situated in Shenzhen, China, while it maintains four manufacturing sites in Hubei, Zhejiang, Jiangxi, and Henan. The Hubei facility is recognized for its USFDA and EU GMP approvals, specializing in the production of high potency and oncology materials within a dedicated oncology workshop, meeting OEB 5 material production standards. Haorui prides itself as a dependable partner for all your pharmaceutical needs.

Hengrui Medicine is a prominent pharmaceutical corporation situated in China, focusing on the exploration, production, manufacturing, and marketing of groundbreaking and superior healthcare goods. It underwent restructuring into a joint-stock company in 1997 and was subsequently listed on the Shanghai Stock Exchange under stock code 600276 in 2000. With a market capitalization exceeding 55 billion USD, the company is ranked among the top 30 pharmaceutical firms globally and employs over 21,900 personnel worldwide. Hengrui is recognized as a pioneer in the field of cancer medications, contrast agents, and surgical innovations.